Last reviewed · How we verify
Macrogol 4000
Macrogol 4000 is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements.
Macrogol 4000 is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements. Used for Constipation, Bowel preparation prior to colonoscopy or other gastrointestinal procedures.
At a glance
| Generic name | Macrogol 4000 |
|---|---|
| Also known as | Paxabel |
| Sponsor | Aboca Spa Societa' Agricola |
| Drug class | Osmotic laxative |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Macrogol (polyethylene glycol) 4000 is a high-molecular-weight polymer that is poorly absorbed in the gastrointestinal tract. It exerts an osmotic effect by retaining water in the intestinal lumen, increasing stool bulk and moisture content, which facilitates easier passage of feces and relieves constipation. It is commonly used as a bowel preparation agent and for chronic constipation management.
Approved indications
- Constipation
- Bowel preparation prior to colonoscopy or other gastrointestinal procedures
Common side effects
- Abdominal bloating
- Abdominal discomfort
- Nausea
- Flatulence
Key clinical trials
- The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation (NA)
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study (PHASE2)
- Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation (PHASE3)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection (NA)
- What Laxative Should be Used After Hip Fracture Surgery? (PHASE4)
- Polyethylene Glycol for Childhood Constipation (PHASE4)
- The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Macrogol 4000 CI brief — competitive landscape report
- Macrogol 4000 updates RSS · CI watch RSS
- Aboca Spa Societa' Agricola portfolio CI